DHS Further Analysis Reports No. 101
Health Economics Review, 2016 6:7 -Published: 11 February 2016
Biology, Diagnosis and Treatment, Epidemiology and Prevention
3ie Impact Evaluation Report 39
Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30409-1
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...demic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
more
The information in this report is up-to-date as of June 2016.
The report, which follows a field visit to the country between 28 May and 6 June, also emphasises the need for international organisations to be mindful of the long present efforts of Greek lawyers and NGOs in the field, and recommends... that new initiatives should be targeted and sustainable.
more
Productive and Inclusive Cities for an Emerging Democratic Republic of Congo